APGE - Apogee Therapeutics, Common Stock - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

APGE is currently covered by 4 analysts with an average price target of $80.85. This is a potential upside of $41.74 (106.72%) from yesterday's end of day stock price of $39.11.

Apogee Therapeutics, Common Stock's activity chart (see below) currently has 0 price targets and 15 ratings on display. The stock rating distribution of APGE is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 41.25% with an average time for these price targets to be met of 126 days.

Highest price target for APGE is $116, Lowest price target is $90, average price target is $94.

Most recent stock forecast was given by SEAMUS FERNANDEZ from GUGGENHEIM on 02-Jul-2025. First documented stock forecast 08-Aug-2023.

Best performing analysts who are covering APGE - Apogee Therapeutics, Common Stock:

Seamus Fernandez David Nierengarten Alex Thompson Akash Tewari

Currently out of the existing stock ratings of APGE, 15 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$116

$76.69 (195.09%)

19 days ago
(02-Jul-2025)

2/5 (40%)

$71.68 (161.73%)

102

Buy

$90

$50.69 (128.95%)

$87

7 months 19 days ago
(02-Dec-2024)

1/4 (25%)

$43.86 (95.06%)

209

Buy

$95

$55.69 (141.67%)

$46

1 years 4 months 16 days ago
(05-Mar-2024)

1/2 (50%)

$35.7 (60.20%)

53

Buy

$75

$35.69 (90.79%)

$29

1 years 4 months 16 days ago
(05-Mar-2024)

1/2 (50%)

$15.7 (26.48%)

140

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is APGE (Apogee Therapeutics, Common Stock) average time for price targets to be met?

On average it took 126 days on average for the stock forecasts to be realized with a an average price target met ratio 41.25

Which analyst has the current highest performing score on APGE (Apogee Therapeutics, Common Stock) with a proven track record?

SEAMUS FERNANDEZ

Which analyst has the current lower performing score on APGE (Apogee Therapeutics, Common Stock) with a proven track record?

AKASH TEWARI

Which analyst has the most public recommendations on APGE (Apogee Therapeutics, Common Stock)?

Seamus Fernandez works at GUGGENHEIM and has 7 price targets and 5 ratings on APGE

Which analyst is the currently most bullish on APGE (Apogee Therapeutics, Common Stock)?

Seamus Fernandez with highest potential upside - $76.69

Which analyst is the currently most reserved on APGE (Apogee Therapeutics, Common Stock)?

Akash Tewari with lowest potential downside - $35.69

Apogee Therapeutics, Common Stock in the News

Apogee Therapeutics stock maintains Buy rating at Citi after positive data

Investing.com – Citi maintained its Buy rating and $95.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE), a $2.77 billion market cap biotech company, following the release of Phase 2a data for its atopic dermatitis treatment APG777. According to InvestingPro data, the company maintains a “GOOD” overall financial health score, with analysts unanimously rating it...

Apogee falls after results from atopic dermatitis trial

[On the table are a stethoscope, a thermometer, a pen and a notebook with the inscription -Atopic dermatitis] Dzmitry Skazau/iStock via Getty Images Apogee Therapeutics (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]) stock fell on Monday despite the announcement that it met its main goal in part A of its mid-stage trial for APG777, an antibody treatment aimed at moderate-to-severe...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?